Odyssean LLC Grows Stake in Vaxcyte, Inc. $PCVX

Odyssean LLC increased its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 211.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,638 shares of the company’s stock after purchasing an additional 42,527 shares during the period. Vaxcyte accounts for 0.6% of Odyssean LLC’s portfolio, making the stock its 4th biggest position. Odyssean LLC’s holdings in Vaxcyte were worth $3,641,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Man Group plc purchased a new position in Vaxcyte during the second quarter valued at $4,745,000. Jupiter Topco LLC bought a new stake in shares of Vaxcyte during the 2nd quarter valued at $1,044,355,000. Elmind Capital LP bought a new stake in shares of Vaxcyte during the 2nd quarter valued at $26,294,524,000. ADAR1 Capital Management LLC purchased a new stake in shares of Vaxcyte in the 2nd quarter worth about $8,489,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Vaxcyte in the 2nd quarter worth about $241,000. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $86.00.

Insider Activity

In other Vaxcyte news, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the transaction, the chief operating officer directly owned 158,494 shares of the company’s stock, valued at approximately $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the transaction, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at $5,979,745.60. This trade represents a 8.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 120,646 shares of company stock worth $6,570,810. 3.30% of the stock is currently owned by company insiders.

Vaxcyte Trading Down 1.3%

Shares of NASDAQ:PCVX opened at $61.09 on Wednesday. The stock has a fifty day simple moving average of $56.91 and a two-hundred day simple moving average of $55.88. Vaxcyte, Inc. has a 12-month low of $29.87 and a 12-month high of $65.00. The stock has a market capitalization of $9.09 billion, a price-to-earnings ratio of -8.01 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period in the previous year, the firm earned ($1.22) earnings per share. As a group, equities research analysts predict that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.